- Home
- TASK vs KNSA Comparison
TASK vs KNSA Comparison
Compare TASK & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TASK
- KNSA
- Stock Information
- Founded
- TASK 2008
- KNSA 2015
- Country
- TASK United States
- KNSA United Kingdom
- Employees
- TASK N/A
- KNSA N/A
- Industry
- TASK Retail: Computer Software & Peripheral Equipment
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- TASK Technology
- KNSA Health Care
- Exchange
- TASK Nasdaq
- KNSA Nasdaq
- Market Cap
- TASK 1.5B
- KNSA 1.4B
- IPO Year
- TASK 2021
- KNSA 2018
- Fundamental
- Price
- TASK $16.77
- KNSA $18.54
- Analyst Decision
- TASK Buy
- KNSA Strong Buy
- Analyst Count
- TASK 8
- KNSA 5
- Target Price
- TASK $17.25
- KNSA $36.60
- AVG Volume (30 Days)
- TASK 285.8K
- KNSA 485.3K
- Earning Date
- TASK 02-26-2025
- KNSA 02-26-2025
- Dividend Yield
- TASK N/A
- KNSA N/A
- EPS Growth
- TASK 29.08
- KNSA N/A
- EPS
- TASK 0.58
- KNSA N/A
- Revenue
- TASK $955,007,000.00
- KNSA $384,098,000.00
- Revenue This Year
- TASK $9.16
- KNSA $60.05
- Revenue Next Year
- TASK $9.71
- KNSA $36.74
- P/E Ratio
- TASK $28.72
- KNSA N/A
- Revenue Growth
- TASK 2.43
- KNSA 54.41
- 52 Week Low
- TASK $10.56
- KNSA $16.56
- 52 Week High
- TASK $19.60
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- TASK 55.41
- KNSA 35.62
- Support Level
- TASK $14.31
- KNSA $17.82
- Resistance Level
- TASK $17.09
- KNSA $19.05
- Average True Range (ATR)
- TASK 0.88
- KNSA 0.63
- MACD
- TASK -0.04
- KNSA -0.08
- Stochastic Oscillator
- TASK 76.26
- KNSA 26.09
About TASK TaskUs Inc.
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to inventive and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.